Brief: Sino Biopharmaceutical Says Application For Clinical Trial On TQB3205 Approved By NMPA
11/03/2026 15:11
March 11 (Reuters) - Sino Biopharmaceutical 1177.HK: APPLICATION FOR CLINICAL TRIAL ON TQB3205 "PAN-KRAS INHIBITOR" APPROVED BY NMPA Further company coverage: 1177.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
Brief: Sino Biopharmaceutical China CDE Accepts New Drug Application For TQB2102 Injection
Sino Biopharmaceutical climbs on plan to raise stake in core unit